Within 24 hours of Samsung Bioepis and Sandoz launching their partnered Pyzchiva (ustekinumab-ttwe) biosimilar to Stelara in the US, the Korean developer has been hit by a lawsuit from originator J&J claiming that a private-label deal with a pharmacy benefit manager violates the terms of the settlement that allowed the biosimilar launch.
J&J Slaps Samsung Bioepis With Stelara Lawsuit In US
As Pyzchiva Biosimilar Launches, Originator Says PBM Deal Breaches Settlement
The same day as Samsung Bioepis and Sandoz launched their partnered Pyzchiva biosimilar rival to Stelara in the US, originator J&J hit the Korean developer with a lawsuit claiming that a private-label commercialization deal with a US pharmacy benefit manager violates the ustekinumab settlement that allowed the firms to launch.
